Updated Clinical Practice Guideline on Use of Gadolinium-Based Contrast Agents in Kidney Disease Issued by the Canadian Association of Radiologists.
Gadolinium based contrast agents
Kidney
Magnetic resonance imaging
Nephrogrenic systemic fibrosis
Journal
Canadian Association of Radiologists journal = Journal l'Association canadienne des radiologistes
ISSN: 1488-2361
Titre abrégé: Can Assoc Radiol J
Pays: United States
ID NLM: 8812910
Informations de publication
Date de publication:
Aug 2019
Aug 2019
Historique:
received:
01
04
2019
accepted:
17
04
2019
pubmed:
1
7
2019
medline:
14
8
2019
entrez:
1
7
2019
Statut:
ppublish
Résumé
In 2017, the Canadian Association of Radiologists issued a clinical practice guideline (CPG) regarding the use of gadolinium-based contrast agents (GBCAs) in patients with acute kidney injury (AKI), chronic kidney disease (CKD), or on dialysis due to mounting evidence indicating that nephrogenic systemic fibrosis (NSF) occurs with extreme rarity or not at all when using Group II GBCAs or the Group III GBCA gadoxetic acid (compared to first generation Group I linear GBCAs). One of the goals of the work group was to re-evaluate the CPG after 24 months to determine the effect of more liberal use of GBCA on reported cases of NSF in patients with AKI, CKD Stage 4 or 5 (estimated glomerular filtration rate [eGFR] < 30 mL/min/1.73 m
Identifiants
pubmed: 31255393
pii: S0846-5371(19)30045-2
doi: 10.1016/j.carj.2019.04.001
pii:
doi:
Substances chimiques
Contrast Media
0
Gadolinium
AU0V1LM3JT
Types de publication
Journal Article
Practice Guideline
Langues
eng
Sous-ensembles de citation
IM
Pagination
226-232Informations de copyright
Copyright © 2019 Canadian Association of Radiologists. Published by Elsevier Inc. All rights reserved.